• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease

    12/5/24 8:00:00 AM ET
    $DNLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNLI alert in real time by email

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor BIIB122 (DNL151) in participants with LRRK2-associated Parkinson's disease (LRRK2-PD). LRRK2 inhibition is a potential therapeutic approach that may slow progression of Parkinson's disease by targeting underlying lysosomal dysfunction implicated in this disease.

    The Phase 2a study is intended to evaluate safety and biomarkers associated with oral daily dosing of BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing. The study is designed to enroll participants into a double-blind treatment period of three months followed by an open label extension. Denali holds the Investigational New Drug application for this Phase 2a study and is leading its design and execution. This study is being funded under a Collaboration and Development Funding Agreement between Denali and a third party. BIIB122 is also being investigated in the ongoing global Phase 2b LUMA study in participants with early-stage Parkinson's disease with or without a LRRK2 mutation, in collaboration with Biogen.

    "We are thrilled to initiate this study and broaden our efforts in evaluating BIIB122 as a potential treatment for people living with Parkinson's disease related to LRRK2 mutations," said Carole Ho, M.D., Chief Medical Officer at Denali. "We look forward to continued collaboration with the Parkinson's community as we aim to generate biomarker and safety data to inform how LRRK2 inhibition may have an impact on the course of this disease."

    "LRRK2 continues to be a prominent target in Parkinson's research, and a priority area of focus for disease-modifying therapies," said Todd Sherer, Ph.D., Chief Mission Officer of The Michael J. Fox Foundation. "The Phase 2a study of BIIB122 is a meaningful milestone in advancing the potential of LRRK2 as a therapeutic approach for people with Parkinson's disease." 

    About LRRK2 and BIIB122 (DNL151)

    Following discovery of the LRRK2 mutation as a pathogenic genetic factor for Parkinson's disease, further research has uncovered that it has the potential to be a novel therapeutic target for Parkinson's disease. Pathogenic mutations in LRRK2 account for 4-5% of familial and 1-2% of sporadic Parkinson's disease.1,2

    BIIB122 (DNL151) is a selective, central nervous system-penetrant small molecule inhibitor of LRRK2 that is hypothesized to improve lysosomal dysfunction.

    Denali's strategic partner Biogen is conducting the global Phase 2b LUMA study of BIIB122, which is expected to enroll approximately 640 participants with early-stage Parkinson's disease, including eligible participants with LRRK2 mutations. More information about the Phase 2b LUMA study (NCT05348785) can be found here.

    The Phase 2a BEACON study is a multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an open label extension in participants with LRRK2-PD, which is defined as Parkinson's disease in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity. This study's purpose is to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122. More information about the Phase 2a BEACON study (NCT06602193) can be found here.

    BIIB122 is an investigational drug that is not approved by any regulatory authority, and its safety and efficacy have not been established.

    About Denali Therapeutics

    Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the blood-brain barrier and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco. For additional information, please visit www.denalitherapeutics.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding Denali's plans, timelines, and expectations related to BIIB122 (DNL151) and its therapeutic potential; the enrollment, timing, and availability and impact of data related to the planned Phase 2a study and any future late-stage studies; the ongoing Phase 2b LUMA study, including expected enrollment; and statements made by MJFF's Chief Mission Officer and Denali's Chief Medical Officer. Actual results are subject to risks and uncertainties and may differ materially from those indicated by these forward-looking statements as a result of these risks and uncertainties, including without limitation, Denali's transition to a late stage clinical drug development company; Denali's and its partners' ability to initiate, enroll patients in, conduct, and complete its ongoing and future clinical trials on expected timelines; Denali's reliance on third parties for the manufacture and supply of its product candidates for clinical trials; the potential for clinical trial results of BIIB122 to differ from preclinical, preliminary or expected results; the risk of adverse events, toxicities, and other undesirable side effects; the risk that results from early clinical biomarker studies will not translate to clinical benefit in late clinical studies; the risk that BIIB122 may not in the future receive regulatory approval necessary to be commercialized; Denali's ability to obtain, maintain, or protect intellectual property rights related to its product candidates; implementation of Denali's strategic plans for its business, product candidates and BBB platform technology; and other risks. In light of these risks, uncertainties, and assumptions, the forward-looking statements in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Information regarding additional risks and uncertainties may be found in Denali's Annual and Quarterly Reports filed on Forms 10-K and 10-Q filed with the Securities and Exchange Commission (SEC) on February 28, 2024, and November 6, 2024, respectively, and Denali's future reports to be filed with the SEC. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results, or to make changes in Denali's expectations, except as required by law.

    References:

    1. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008;7(7):583-90.
    2. Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem. 2016;139 Suppl 1:59-74. Epub 2016/04/18.

    Investor Contact

    Laura Hansen, Ph.D.

    Vice President, Investor Relations

    (650) 452-2747

    [email protected]

    Media Contact

    Rich Allan

    FGS Global

    (503) 851-0807

    [email protected]



    Primary Logo

    Get the next $DNLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • What recent clinical study did Denali Therapeutics initiate?

      Denali Therapeutics has initiated a global Phase 2a clinical study called BEACON for the investigational drug BIIB122 (DNL151), aimed at treating participants with LRRK2-associated Parkinson's disease.

    • What is the primary goal of the BEACON study and how many participants will it involve?

      The Phase 2a study is designed to evaluate the safety and biomarkers of the drug by enrolling approximately 50 participants confirmed to have LRRK2 mutations, following a three-month double-blind treatment period and an open label extension.

    • What is BIIB122 and what therapeutic approach does it represent in the context of Parkinson's disease?

      BIIB122 is a selective small molecule inhibitor of LRRK2 that aims to improve lysosomal dysfunction, which is implicated in the progression of Parkinson's disease.

    • Is Denali Therapeutics working independently on BIIB122, or are they partnering with other companies?

      Denali Therapeutics is collaborating with Biogen, which is also conducting the global Phase 2b LUMA study of BIIB122 involving approximately 640 participants.

    • What is the regulatory status of BIIB122?

      The safety and efficacy of BIIB122 have not been established as it is still an investigational drug and is not currently approved by any regulatory authority.

    Recent Analyst Ratings for
    $DNLI

    DatePrice TargetRatingAnalyst
    4/10/2025Neutral → Overweight
    Cantor Fitzgerald
    3/7/2025$41.00 → $33.00Overweight
    Morgan Stanley
    2/11/2025$31.00Buy
    Deutsche Bank
    1/7/2025$31.00Outperform
    Robert W. Baird
    1/3/2025Outperform
    William Blair
    12/16/2024$37.00Hold → Buy
    Stifel
    10/10/2024Mkt Perform
    Raymond James
    10/7/2024Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $DNLI
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences

      O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar

      4/8/24 8:00:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • DEAN BANKS APPOINTED CEO OF INDIGO AG AND CEO-PARTNER OF FLAGSHIP PIONEERING

      Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022 Company Closes Financing Round at Nearly $270 Million Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors  CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Be

      1/9/24 8:44:00 AM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders

      Memorandum of Understanding with UK Government Outlines Areas of Cooperation CAMBRIDGE, Mass. and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.

      11/27/23 7:01:00 PM ET
      $DNLI
      $FHTX
      $MCRB
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $DNLI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. "The completion of our BLA submission for tividenofusp alfa represents a pivotal milestone—not only in our commitment to delivering a potentially transformative therapy to individuals living with Hunter syndrome, but also in Denali's evolution as a fully integrated, late-stage development and commercial organization," said Ryan Watts, Ph.D., CEO of Denali Therapeutics. "We are now preparing for commercial launch in late 2025 or early 2026. If approved, tividenofusp alfa would be t

      5/6/25 4:01:00 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

      Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026Alignment through recent interactions with CDER on path to accelerated approval and conversion to full approval for tividenofusp alfaProductive collaboration continues under START for an accelerated development and approval path for DNL126 SOUTH SAN FRANCISCO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), today announced that the company's initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II) has bee

      4/2/25 8:00:44 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

      SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights. "In 2024, we made significant strides across our portfolio, particularly with our Enzyme Transport Vehicle (ETV) programs, achieving a path to a potential accelerated approval for our lead program in MPS II," said Ryan Watts, Ph.D., CEO of Denali. "In 2025, we will continue expanding our capabilities as we prepare for our first potential product launch of tividenofusp alfa. In addition, we are prioritizing opportunities to expand and accelerate our TV portfolio and a

      2/27/25 4:01:00 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Ho Carole sold $308,291 worth of shares (15,162 units at $20.33), decreasing direct ownership by 8% to 175,673 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/8/25 8:26:37 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • COFO and Secretary Schuth Alexander O. sold $308,291 worth of shares (15,162 units at $20.33), decreasing direct ownership by 6% to 244,308 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/8/25 8:25:44 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President and CEO Watts Ryan J. sold $750,955 worth of shares (36,916 units at $20.34), decreasing direct ownership by 13% to 253,071 units (SEC Form 4)

      4 - Denali Therapeutics Inc. (0001714899) (Issuer)

      1/8/25 8:24:43 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DNLI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $DNLI
    SEC Filings

    See more
    • Denali Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Denali Therapeutics from Neutral to Overweight

      4/10/25 8:28:39 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley resumed coverage on Denali Therapeutics with a new price target

      Morgan Stanley resumed coverage of Denali Therapeutics with a rating of Overweight and set a new price target of $33.00 from $41.00 previously

      3/7/25 8:22:55 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Deutsche Bank initiated coverage on Denali Therapeutics with a new price target

      Deutsche Bank initiated coverage of Denali Therapeutics with a rating of Buy and set a new price target of $31.00

      2/11/25 7:04:19 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Denali Therapeutics Inc.

      SC 13G - Denali Therapeutics Inc. (0001714899) (Subject)

      11/12/24 12:52:28 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      11/12/24 9:55:15 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Denali Therapeutics Inc.

      SC 13G/A - Denali Therapeutics Inc. (0001714899) (Subject)

      11/8/24 10:52:39 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Denali Therapeutics Inc.

      10-Q - Denali Therapeutics Inc. (0001714899) (Filer)

      5/6/25 4:04:50 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Denali Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Denali Therapeutics Inc. (0001714899) (Filer)

      5/6/25 4:03:05 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Denali Therapeutics Inc.

      DEFA14A - Denali Therapeutics Inc. (0001714899) (Filer)

      4/17/25 4:06:10 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care